S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
Log in
(Ad)
Paul Mampilly correctly predicted every bull and bear market over the last two decades. He made millions. His new "Dow 100,000" prediction is his boldest yet. Even more stunning... Paul reveals how you could make millions as it unfolds.

NASDAQ:FTSV - Forty Seven Stock Price, Forecast & News

$43.65
+1.80 (+4.30 %)
(As of 01/23/2020 04:00 PM ET)
Add
Compare
Today's Range
$40.41
Now: $43.65▼
$44.85
50-Day Range
$14.19
MA: $37.41▼
$45.74
52-Week Range
$5.53
Now: $43.65▼
$49.50
Volume629,773 shs
Average Volume703,738 shs
Market Capitalization$1.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.53
Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FTSV
Previous Symbol
CUSIPN/A
CIKN/A
Webhttp://www.fortyseveninc.com/
Phone650-352-4150

Debt

Debt-to-Equity Ratio0.01
Current Ratio7.48
Quick Ratio7.48

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.29 per share
Price / Book10.17

Profitability

EPS (Most Recent Fiscal Year)($3.75)
Net Income$-70,370,000.00
Net MarginsN/A
Return on Equity-63.94%
Return on Assets-54.76%

Miscellaneous

Employees57
Outstanding Shares42,276,000
Market Cap$1.85 billion
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive FTSV News and Ratings via Email

Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:FTSV Rates by TradingView

(Ad)

Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

What is Forty Seven's stock symbol?

Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) issued its earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.38). The firm had revenue of $15.68 million for the quarter, compared to the consensus estimate of $15.80 million. View Forty Seven's Earnings History.

When is Forty Seven's next earnings date?

Forty Seven is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Forty Seven.

What price target have analysts set for FTSV?

11 analysts have issued 12 month price targets for Forty Seven's shares. Their forecasts range from $18.00 to $55.00. On average, they expect Forty Seven's share price to reach $40.82 in the next year. This suggests that the stock has a possible downside of 6.5%. View Analyst Price Targets for Forty Seven.

What is the consensus analysts' recommendation for Forty Seven?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Forty Seven.

What are Wall Street analysts saying about Forty Seven stock?

Here are some recent quotes from research analysts about Forty Seven stock:
  • 1. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (1/22/2020)
  • 2. Mizuho analysts commented, "We initiate coverage of FTSV with a Buy rating and $18 PT. We like the speed- to-market program for 5F9 (pivotal readout by 4Q20). We also like the pursuit of a novel mechanism in immuno-oncology, innate immunity via CD47. FTSV has cash into 2021 and readouts that should serve as valuation inflection points." (9/11/2019)

Has Forty Seven been receiving favorable news coverage?

News coverage about FTSV stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Forty Seven earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Forty Seven.

Are investors shorting Forty Seven?

Forty Seven saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 2,050,000 shares, a decline of 9.3% from the November 28th total of 2,260,000 shares. Based on an average trading volume of 658,400 shares, the short-interest ratio is currently 3.1 days. Approximately 8.9% of the company's shares are short sold. View Forty Seven's Current Options Chain.

Who are some of Forty Seven's key competitors?

What other stocks do shareholders of Forty Seven own?

Who are Forty Seven's key executives?

Forty Seven's management team includes the folowing people:
  • Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)
  • Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)
  • Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)
  • Mr. Mark Chao, Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.

When did Forty Seven IPO?

(FTSV) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

How do I buy shares of Forty Seven?

Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Forty Seven's stock price today?

One share of FTSV stock can currently be purchased for approximately $43.65.

How big of a company is Forty Seven?

Forty Seven has a market capitalization of $1.85 billion. The company earns $-70,370,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis. Forty Seven employs 57 workers across the globe.View Additional Information About Forty Seven.

What is Forty Seven's official website?

The official website for Forty Seven is http://www.fortyseveninc.com/.

How can I contact Forty Seven?

Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]


MarketBeat Community Rating for Forty Seven (NASDAQ FTSV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  127 (Thanks for Voting!)
Underperform Votes:  114 (Thanks for Voting!)
Total Votes:  241
MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote "Outperform" if you believe FTSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Correction
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel